Petros Pharmaceuticals, Inc.
PTPI
$0.01
$0.001.41%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -81.97% | -44.14% | -20.67% | -12.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -81.97% | -44.14% | -20.67% | -12.20% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 0.31% | -30.33% | -34.90% | -46.92% | -50.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.31% | -44.66% | -54.86% | -67.87% | -72.10% |
| Operating Income | -0.31% | 46.88% | 48.85% | 58.17% | 57.01% |
| Income Before Tax | -538.21% | -2,942.86% | -36.06% | 64.23% | 91.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -538.21% | -2,942.86% | -36.06% | 64.23% | 91.36% |
| Earnings from Discontinued Operations | 147.11% | 52.85% | -0.45% | -376.45% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 113.36% | -48.57% | -17.93% | -61.24% | -75.41% |
| EBIT | -0.31% | 46.88% | 48.85% | 58.17% | 57.01% |
| EBITDA | -0.80% | 66.48% | 67.20% | 77.37% | 75.99% |
| EPS Basic | 88.36% | 64.46% | 68.92% | 68.10% | 42.21% |
| Normalized Basic EPS | -190.11% | -157.89% | 89.75% | 95.61% | 99.59% |
| EPS Diluted | 88.36% | 64.46% | 68.92% | 68.10% | 42.21% |
| Normalized Diluted EPS | -190.11% | -157.89% | 89.75% | 95.61% | 99.59% |
| Average Basic Shares Outstanding | 8,612.66% | 7,062.83% | 4,088.34% | 395.67% | 268.66% |
| Average Diluted Shares Outstanding | 8,612.66% | 7,062.83% | 4,088.34% | 395.67% | 268.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |